|
M.V. Leonova
Bempedoic acid – a new drug in lipid-lowering therapy
|
№14 / 2023
|
|
E.V. Biryukova, M.V. Shinkin, I.A. Morozovа
Modern practice of lipid-lowering pharmacotherapy: the choice of the optimal fixed combination
|
№3 / 2023
|
|
O.A. Polyakova, Yu.M. Tkachenko, O.D. Ostroumova
Relationship between non-alcoholic fatty liver disease and cardiovascular disease: focus on the use of ursodeoxycholic acid
|
№1-2 / 2023
|
|
S.S. Apetov, V.V. Apetova
Is there a “window of therapeutic opportunity” for testosterone replacement therapy for age-related hypogonadism in men?
|
№6 / 2022
|
|
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
Efficacy and safety of ertugliflozin: results of the VERTIS CV sub-study in patients receiving a stable dose of insulin
|
№4 / 2022
|
|
D.I. Trukhan, D.S. Ivanova
Drug safety in real clinical practice: focus on protective therapy
|
№3 / 2022
|
|
O.D. Ostroumova (1, 2), A.I. Kochetkov (1), E.E. Pavleeva (3), O.V. Golovina (1), N.A. Arablinsky (4)
The relationship of cardiovascular disease with increased intestinal permeability: results from scientific and controlled clinical trials. Focus on the potential of rebamipide
|
№3 / 2021
|
|
A.V. Nikolaeva, L.T. Pimenov
CARDIORENAL RELATIONSHIPS IN PATIENTS WITH PRIMARY HYPOTHYROIDISM DEPENDING ON THE PHASE OF DISEASE
|
№20 / 2016
|
|
D.V. Nebieridze (1), T.V. Kamyshova (1), A.A. Sarycheva (2)
EVALUATION OF FREQUENCY OF TARGET ORGAN DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION WHO APPLIED FOR AN OUTPATIENT APPOINTMENT WITH A DOCTOR FOR THE FIRST TIME
|
№9 / 2016
|
|
N.Yu. Karpova, M.A. Rashid, N.A. Shostak, T.V. Kazakova
CARDIOVASCULAR DISEASES AND OSTEOPOROSIS
|
№s5-13 / 2013
|
|
M.Yu. Gilyarov
Place Of Aspirin In The Therapy Of Atherothrombosis And Its Complications
|
№15 / 2011
|
|
I. Samylina, A.Sorokina, N. Pyatigorskaya
Hawthorn (crataegus): Options For Medical Use
|
№8 / 2010
|
Русский
